Esperion Therapeutics (ESPR) Tops Q4 EPS by 50c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- US stocks on course for lower open as AI jitters hit Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% as attacks halt Saudi pipeline
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
February 22, 2022 7:00 AM ESTÂ Unprecedented CLEAR Outcomes Study Achieved 90% MACE Accumulation in February 2022
U.S. Net Product Revenue of NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets Grew 12% Sequentially to $12.2 Million in the Fourth Quarter 2021 and Over 200% for the Full Year 2021
 Prescriptions Grew 9% During the Quarter; Approximately 70,000 Patients Have Filled a Prescription for NEXLETOL Tablets or NEXLIZET Tablets Since Launch
 Strengthened Capital Position in Fourth Quarter 2021 with $209 Million Financing Securing Path to CLEAR Outcomes Topline and Beyond
ANN ARBOR, Mich., Feb. 22,... More
